Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1282559 | 0.92 | PTPN11 (0.31) | ALDH1A1PTPN11PKM | |
| SCHEMBL1282896 | 0.90 | KDM4E (0.32) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL1282607 | 0.90 | MET (0.32) | — | |
| SCHEMBL1282205 | 0.89 | PTPN11 (0.33) | ALDH1A1PTPN11PKM | |
| SCHEMBL1282983 | 0.89 | PTPN11 (0.32) | ALDH1A1PTPN11PKM | |
| SCHEMBL1282937 | 0.89 | PTPN11 (0.32) | PTPN11PKM | |
| SCHEMBL1283461 | 0.88 | MLYCD (0.34) | PTPN11PKM | |
| SCHEMBL1283728 | 0.88 | PTPN11 (0.31) | PTPN11PKM | |
| SCHEMBL1282229 | 0.88 | PTPN11 (0.34) | KDM4EALDH1A1HPGDHSD17B10USP2 | |
| SCHEMBL1283632 | 0.88 | PTPN11 (0.31) | PTPN11PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | claimed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | KDM4E 3529/4885ALDH1A1 2614/4885HPGD 1895/4885 |
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | KDM4E 4020/4885ALDH1A1 4530/4885HPGD 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.